Skip to main content

Table 4 Incidence of bevacizumab-related adverse events

From: Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry

  

All patients

<65 years

65-75 years

≥75 years

  

(n = 3,187)

(n = 2,126)

(n = 932)

(n = 129)

  

n (%)

n (%)

n (%)

n (%)

New or worsening hypertension

All

115 (3.6)

71 (3.3)

34 (3.6)

10 (7.8)

 

G3-5

51 (1.6)

31 (1.5)

16 (1.7)

4 (3.1)

Thromboembolic event

All

105 (3.3)

65 (3.1)

36 (3.9)

4 (3.1)

 

G3-5

82 (2.6)

49 (2.3)

30 (3.2)

3 (2.3)

Proteinuria

All

59 (1.9)

40 (1.9)

17 (1.8)

2 (1.6)

 

G3-5

13 (0.4)

8 (0.4)

5 (0.5)

0 (0)

Bleeding

All

40 (1.3)

24 (1.1)

15 (1.6)

1 (0.8)

 

G3-5

19 (0.6)

12 (0.6)

7 (0.8)

0 (0)

Gastrointestinal perforation

All

8 (0.3)

5 (0.2)

3 (0.3)

0 (0)

 

G3-5

4 (0.1)

3 (0.1)

1 (0.1)

0 (0)